Plain-English translation of NCT07010835 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called to see if it can safely help people with moderate to severe lupus by reducing how active their disease is. The study has two main phases: first, researchers will test different doses to find the safest and most effective amounts, and then they will compare the medication to a placebo (a dummy pill) to confirm whether it really works.
Lupus is a serious autoimmune disease that can cause lasting damage to the body, and current treatments don't work well enough for many patients. This trial exists to see if this new treatment could offer people with moderate to severe lupus a better option to control their disease and improve their quality of life.
You likely qualify if…
You likely don't qualify if…
In this trial, you would either receive different doses of the medication (in the first phase) or be randomly assigned to receive either the medication or a placebo (in the second phase). You would visit the study clinic regularly for check-ups, blood tests, and other assessments to see how the medication affects your lupus and to monitor for any side effects. The trial involves both a dose-escalation stage, where researchers slowly increase the amount of medication to find the safest dose, and an efficacy stage, where they measure how well the medication reduces your lupus activity.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Excyte Biopharma Ltd
Enrollment target
~189 participants
Started
August 2025
Primary completion
June 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xiaofeng Zeng, Doctor of Medicine
Excyte Biopharma Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.